A predictive value of von Willebrand factor for early response to Bevacizumab therapy in recurrent glioma
- 135 Downloads
Bevacizumab (BV), a neutralizing monoclonal antibody against the vascular endothelial growth factor ligand, is recognized as a potent anti-angiogenic agent with antitumor activity. The aim of this single-center, retrospective, longitudinal study was to investigate the possible predictive value of baseline demographic, clinical and laboratory parameters for early 3-month response to BV therapy in patients with recurrent glioma. Forty-nine patients with recurrent glioma received BV at 10 mg/kg intravenously every 3 weeks alone or in association with chemotherapy were included in this study. Blood samples were collected from all patients before the first (baseline), the second and the third administration of BV. After 3 months of BV therapy, patients with partial response were defined as responders whereas patients with stable or progressive disease were defined as non-responders. The median overall follow-up was 8 months (range 1–73), the median overall survival (OS) was 8 months (95% CI 6–10) and the median progression free survival (PFS) was 4 months (95% CI 3–5). Thirty-five % of patients were responders and showed significantly lower von Willebrand factor (VWF) levels than non-responders at all sample times (p < .02 for all). Also, on multivariate analysis the baseline VWF value was the only predictor for an early response to BV therapy. Furthermore, D-dimer and prothrombin fragment 1+2 were predictive factors for OS while Karnofsky performance status resulted predictive for PFS. VWF antigen value is a possible predictive biomarker for an early 3-month response to BV therapy in recurrent glioma.
KeywordsBrain neoplasia Recurrent glioma Bevacizumab therapy Coagulation Von Willebrand factor
Associazione Italiana Tumori Cerebrali (AITC) supported this research.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 7.Colavolpe C, Chinot O, Metellus P, Mancini J, Barrie M, Bequet-Boucard C, Tabouret E, Mundler O, Figarella-Branger D, Guedj E (2012) FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan. Neuro Oncology 14(5):649–657. https://doi.org/10.1093/neuonc/nos012 CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Harris RJ, Cloughesy TF, Pope WB, Nghiemphu PL, Lai A, Zaw T, Czernin J, Phelps ME, Chen W, Ellingson BM (2012) 18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. Neuro Oncology 14(8):1079–1089. https://doi.org/10.1093/neuonc/nos141 CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Kickingereder P, Wiestler B, Burth S, Wick A, Nowosielski M, Heiland S, Schlemmer HP, Wick W, Bendszus M, Radbruch A (2015) Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma. Neuro Oncology 17(8):1139–1147. https://doi.org/10.1093/neuonc/nov028 CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Choi SH, Jung SC, Kim KW, Lee JY, Choi Y, Park SH, Kim HS (2016) Perfusion MRI as the predictive/prognostic and pharmacodynamic biomarkers in recurrent malignant glioma treated with bevacizumab: a systematic review and a time-to-event meta-analysis. J Neurooncol 128(2):185–194. https://doi.org/10.1007/s11060-016-2102-4 CrossRefPubMedGoogle Scholar
- 11.Chen C, Huang R, MacLean A, Muzikansky A, Mukundan S, Wen PY, Norden AD (2013) Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival. J Neurooncol 115(2):267–276. https://doi.org/10.1007/s11060-013-1225-0 CrossRefPubMedGoogle Scholar
- 12.Toft A, Urup T, Christensen IJ, Michaelsen SR, Lukram B, Grunnet K, Kosteljanetz M, Larsen VA, Lassen U, Broholm H, Poulsen HS (2018) Biomarkers in recurrent grade III glioma patients treated with bevacizumab and irinotecan. Cancer Invest 2:1–10. https://doi.org/10.1080/07357907.2018.1430818 CrossRefGoogle Scholar
- 14.Rodríguez Garzotto A, Díaz-García CV, Agudo-López A, Prieto García E, Ponce S, López-Martín JA, Paz-Ares L, Iglesias L, Agulló-Ortuño MT (2016) Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer. Med Oncol 33(10):105. https://doi.org/10.1007/s12032-016-0824-y CrossRefPubMedGoogle Scholar
- 25.Lubberts S, Boer H, Altena R, Meijer C, van Roon AM, Zwart N, Oosting SF, Kamphuisen PW, Nuver J, Smit AJ, Mulder AB, Lefrandt JD, Gietema JA (2016) Vascular fingerprint and vascular damage markers associated with vascular events in testicular cancer patients during and after chemotherapy. Eur J Cancer 63:180–188. https://doi.org/10.1016/j.ejca.2016.05.022 CrossRefPubMedGoogle Scholar
- 26.Nishigori N, Matsumoto M, Koyama F, Hayakawa M, Hatakeyayama K, Ko S, Fujimura Y, Nakajima Y (2015) von Willebrand factor-rich platelet thrombi in the liver cause sinusoidal obstruction syndrome following oxaliplatin-based chemotherapy. PLoS ONE 10(11):e0143136. https://doi.org/10.1371/journal.pone.0143136 CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Gritti G, Cortelezzi A, Bucciarelli P, Rezzonico F, Lonati S, LaMarca S et al (2011) Circulating and progenitor endothelial cells are abnormal in patients with different types of von Willebrand disease and correlate with markers of angiogenesis. Am J Hematol 86(3):650–656CrossRefPubMedGoogle Scholar
- 31.Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699–708CrossRefPubMedPubMedCentralGoogle Scholar